Journal article

Publication year: 2020

Pages: 188-192

Journal: International Journal of Cardiology

Volume number: 317

ISSN: 0167-5273

eISSN: 1874-1754

Open access status: Hybrid

DOI Link: https://doi.org/10.1016/j.ijcard.2020.05.044

Publisher: Elsevier

Abstract: 

Background: RESPITE evaluated patients with pulmonary arterial hypertension and an inadequate response to phosphodiesterase type 5 inhibitors (PDE5i) who switched to riociguat. This post hoc analysis assessed response to this switch in parameters associated with clinical improvement.

Methods: RESPITE was a 24-week, uncontrolled pilot study (n = 61). Differences in functional, hemodynamic, and cardiac function parameters, REVEAL risk score (RRS), and biomarkers were compared between responders (free from clinical worsening, World Health Organization functional class I/II, and >= 30 m improvement in 6-min walking distance at Week 24) and non-responders.

Results: Of 51 patients (84%) completing RESPITE, 16 (31%) met the responder endpoint. At baseline, there were significant differences between responders and non-responders in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), growth/differentiation factor 15 (GDF-15), and RRS, whereas there were no differences in hemodynamics or cardiac function. At Week 24, responders had significant improvements in pulmonary arterial compliance, pulmonary vascular resistance, and mean pulmonary arterial pressure, while non-responders showed no significant change. Cardiac efficiency and stroke volume index significantly improved irrespective of responder status.

Conclusions: NT-proBNP, GDF-15, and RRS were identified as potential predictors of response in patients switching from PDE5i to riociguat. Further prospective controlled studies are needed to confirm the association of these parameters with response. (c) 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Harvard Citation style: Benza, R., Corris, P., Klinger, J., Langleben, D., Naeije, R., Simonneau, G., et al. (2020) Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE, International Journal of Cardiology, 317, pp. 188-192. https://doi.org/10.1016/j.ijcard.2020.05.044

APA Citation style: Benza, R., Corris, P., Klinger, J., Langleben, D., Naeije, R., Simonneau, G., Ghofrani, H., Jansa, P., Rosenkranz, S., Scelsi, L., Thenappan, T., Raina, A., Meier, C., Busse, D., & Hoeper, M. (2020). Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. International Journal of Cardiology. 317, 188-192. https://doi.org/10.1016/j.ijcard.2020.05.044